Targeted clinical research to address select viral infections

Ended Definitive Contract Awarded Last action

Contract number
HHSN272201600015C
Awardee
Awarding agency
Obligated
$5,635,565

Award facts

Opportunity
Contract value 100% obligated
$5,635,564.60 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 13 offers Negotiated Proposal / Quote
Pricing
Cost No Fee
Place of performance
Seattle, WA 98109, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00017 -$3,620
Other Administrative Action P00016 $0
Other Administrative Action P00015 $0
Other Administrative Action P00014 $0
Exercise an Option P00013 $237,480
Other Administrative Action P00012 $0
Funding Only Action P00011 -$2,143
Vendor DUNS or Name Change - Non-Novation P00010 $0
Other Administrative Action P00009 $1,120,409
Other Administrative Action P00008 $0
Funding Only Action P00007 -$12,978
Other Administrative Action P00006 $0
Funding Only Action P00005 · To conduct a clinical trial to evaluate the efficacy of a patient-collected dried blood spot CMV PCR testing platform in an allogeneic hematopoietic cell… $1,476,477
Other Administrative Action P00004 · To extend the completion date of option one to december 31, 2020 at no additional cost and add far clauses 52.204-25 and 52.244-6. $0
Exercise an Option 2 · Option one. 11/07/2017 - 11/06/2019. Targeted clinical research to address select viral infections. $1,321,202
Change Order 1 $0
Other Administrative Action 3 · Option one. 11/07/2017 - 11/06/2019. Targeted clinical research to address select viral infections. $0
Original award $1,498,737
Show all 18

About this award

Written by GovTribe AI ·

This $5,635,564.60 cost-reimbursable definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance), a non-profit medical research organization. The contract supports targeted clinical research to address select viral infections. There was no set-aside designation.

Under the contract, Fred Hutchinson Cancer Center is serving as the prime contractor, with several major subcontractors including MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and the University of Washington. These subcontractors are providing clinical trial site services, laboratory testing, and other research support. The contract has an ultimate completion date of December 31, 2025.

Subawards

Subcontractor Amount Awarded
The Univeristy Of Texas M.d. Anderson Cancer Center TO CONDUCT A CLINICAL TRIAL TO EVALUATE THE EFFICACY OF A PATIENT-COLLECTED DRIED BLOOD SPOT CMV PCR TESTING PLATFORM IN AN ALLOGENEIC HEMATOPOIETIC CELL… $15,604
Sloan-Kettering Institute For Cancer Research TO CONDUCT A CLINICAL TRIAL TO EVALUATE THE EFFICACY OF A PATIENT-COLLECTED DRIED BLOOD SPOT CMV PCR TESTING PLATFORM IN AN ALLOGENEIC HEMATOPOIETIC CELL… $74,151

Quick answers

Who was awarded contract HHSN272201600015C?

HHSN272201600015C was awarded to Fred Hutchinson Cancer Center by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2016.

How much is contract HHSN272201600015C worth?

The government has obligated $5,635,565 on HHSN272201600015C.

Was contract HHSN272201600015C competed?

The extent of competition for HHSN272201600015C was full and open competition. The government received 13 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login